recombinant human il12/15-pdl1b oncolytic hsv-1 injection (vero cell))
Biologicalexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2021 (NCT04806464)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06124001 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2023 | Government of China, Zhejiang University |
| NCT06126510 | Phase 2 | Jul 18, 2023 | Government of China, Peking University |
| NCT06008925 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2022 | Government of China, Peking University |
| NCT06746480 | Phase 2 | Mar 19, 2022 | Government of China, Zhejiang University |
| NCT05162118 | Phase 1/Phase 2 (Phase 2) | Jan 4, 2022 | Zhejiang University |
| NCT04758897 | Phase 1 | Apr 14, 2021 | Government of China, Huazhong University of Science and Technology |
| NCT04806464 | Phase 1 | Mar 16, 2021 | Government of China, Zhejiang University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 6 | 6 | 2 | 2021 |
| Zhejiang University | Academic/Hospital | 4 | 1 | 2 | 2021 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1